210 related articles for article (PubMed ID: 36539670)
21. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
22. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Alvarez A; Bernal AM; Anampa J
Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
[TBL] [Abstract][Full Text] [Related]
23. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
West MT; Goodyear SM; Hobbs EA; Kaempf A; Kartika T; Ribkoff J; Chun B; Mitri ZI
Oncologist; 2023 Aug; 28(8):682-690. PubMed ID: 36946994
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach E; Keskinkilic M; Wood S; Canning M; Kalinsky K
Curr Treat Options Oncol; 2023 Sep; 24(9):1103-1119. PubMed ID: 37314645
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Hong K; Yao L; Sheng X; Ye D; Guo Y
Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
30. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
31. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
[TBL] [Abstract][Full Text] [Related]
32. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
Harbeck N; Bartlett M; Spurden D; Hooper B; Zhan L; Rosta E; Cameron C; Mitra D; Zhou A
Future Oncol; 2021 Jun; 17(16):2107-2122. PubMed ID: 33663223
[No Abstract] [Full Text] [Related]
34. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
36. Retrospective registry of patients with locally advanced/metastatic HR
Chavarría Piudo N; Blancas I; González Flores E; Henao Carrasco F; López Álvarez P; Morales Pancorbo D; Gámez Casado S; Lomas Garrido MC; Rodríguez García JM; Martínez Guisado A; Sánchez Vega A; Ruíz Borrego M
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38831191
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract][Full Text] [Related]
38. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
[TBL] [Abstract][Full Text] [Related]
39. Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M; Takada M; Nakayama T; Masuda N; Shiheido H; Cai Z; Huang YJ; Kawaguchi T; Tanizawa Y
Breast Cancer Res Treat; 2023 Jan; 197(2):435-447. PubMed ID: 36414795
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review.
Wang W; Wu J; Chen K; Wang X; Shao X
Technol Cancer Res Treat; 2023; 22():15330338231173504. PubMed ID: 37186799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
